This inventor holds 3 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 5 EPO patents. Top assignee: Nymox Corporation. Active years: 2024-2026.
Company Filing History:
Years Active: 2024-2026
Title: The Innovative Contributions of Paul Averback
Introduction
Paul Averback is a notable inventor based in Nassau, Bahamas. He has made significant contributions to the field of medical technology, particularly in the treatment of prostate cancer and lower urinary tract symptoms (LUTS). With two patents to his name, Averback's work reflects a commitment to improving patient outcomes through innovative solutions.
Latest Patents
Averback's latest patents include a method for the focal treatment of prostate cancer. This method involves administering a composition that contains a therapeutically effective amount of a pharmaceutically active ingredient. The goal is to induce necrosis in low-grade unifocal prostate cancer tumors, thereby reducing cancer incidence, grade, and progression in the affected hemi-prostate. His second patent focuses on enhancing the therapeutic efficacy of Fexapotide Triflutate in treating LUTS. This method includes administering the composition at least twice over a period of more than one year, which has shown to improve urinary flow and reduce nocturia compared to standard treatment.
Career Highlights
Averback is associated with Nymox Corporation, a company dedicated to developing innovative medical solutions. His work at Nymox has been instrumental in advancing treatments that address significant health issues faced by patients.
Collaborations
[This section has been skipped.]
Conclusion
Paul Averback's contributions to medical technology through his patents demonstrate his dedication to improving healthcare solutions. His innovative methods for treating prostate cancer and LUTS highlight the importance of research and development in the medical field.